Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00301106Phase 1Terminated

Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver

Role: lead

NCT00072098Phase 1Terminated

Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer

Role: lead

NCT00849459Phase 1Completed

Gene Therapy in Treating Women With Metastatic Breast Cancer

Role: lead

All 3 trials loaded